Ridgeback Biotherapeutics is a biotech company based in Miami. Its focus is on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases that have limited treatment options or none at all.
Ridgeback Biotherapeutics developed LAGEVRIO™ (molnupiravir), an oral antiviral COVID-19 medicine distributed through Merck.
Its website was redesigned, a professional brand established, and more information was made available for the press. The site is modern, fresh, clean, accessible, and professional. The website is light, organized, easy to navigate, fast-loading, and provides a highly user-friendly experience on all devices (i.e. responsive design/mobile-friendly) and modern browsers.
